Filing Flows › 8-K events › Bioxytran

Bioxytran: other events

Form 8-K filed Nov 5, 2026 · items 8.01

FDA decisionsBioxytran Secures Attested Free Sale Certification for A-SUQAR ® , Opening the Path to the UAE and Gulf Markets

What the filing says

Bioxytran Secures Attested Free Sale Certification for A-SUQAR ® , Opening the Path to the UAE and Gulf Markets Non-systemic, pre-meal chewable nutraceutical designed to help blunt post-meal blood sugar spikes enters a region where roughly 7.5 million adults in the UAE, Saudi Arabia and Kuwait are living with diabetes

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Other recent fda decisions

• Biovie Nov 6, 2026
• Acrivon Therapeutics Nov 6, 2026
• Entera Bio Nov 6, 2026
• Precision Biosciences Nov 5, 2026
• Sintx Technologies Nov 5, 2026
• Microbot Medical Nov 5, 2026
• Palvella Therapeutics Nov 5, 2026
• ANI Pharmaceuticals Nov 5, 2026
• Teleflex Nov 5, 2026
• Schrodinger Nov 4, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.